Cannabinoid Cb1 Receptor Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
CB1 (cannabinoid receptor type 1) neurons represent one of the most abundant neuronal populations in the mammalian brain, expressing the highest density of G protein-coupled receptors (GPCRs) in the central nervous system. These neurons play a critical role in modulating synaptic transmission through retrograde signaling mechanisms, making them essential regulators of neural circuit function and plasticity. [1]
| Property | Value | [2]
|----------|-------| [3]
| Category | Receptor neurons | [4]
| Primary Receptor | CB1 (encoded by CNR1 gene) | [5]
| Neurotransmitter | Endocannabinoids (2-AG, anandamide) | [6]
| Signal Transduction | Gi/o protein-coupled inhibition of adenylate cyclase | [7]
| Brain Regions | Basal ganglia, cerebellum, hippocampus, cortex, hypothalamus |
| Expression Pattern | Presynaptic terminals (axonal), some somatic |
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:0000197 | sensory receptor cell |
The CB1 receptor is a Class A GPCR encoded by the CNR1 gene located on chromosome 6q14-q15. The receptor consists of:
CB1 receptors are activated by endogenous cannabinoids (endocannabinoids):
| Ligand | Full Name | Synthesis | Primary Action |
|---|---|---|---|
| 2-AG | 2-Arachidonoylglycerol | DAGL-mediated cleavage of membrane phospholipids | Full agonist |
| AEA | Anandamide (N-arachidonoylethanolamine) | NAPE-PLD enzymatic synthesis | Partial agonist |
Upon activation, CB1 receptors couple to Gi/o proteins leading to:
CB1 neurons mediate a unique form of retrograde synaptic transmission:
| Brain Region | CB1 Function | Behavioral Output |
|---|---|---|
| Hippocampus | Modulates LTPmechanisms/long-term-potentiation)/LTD, memory formation | Learning and memory |
| Basal Ganglia | Regulates dopamine release, motor control | Movement initiation |
| Cerebellum | Controls Purkinje cell function | Motor coordination |
| Cortex | Regulates pyramidal neuron activity | Cognitive processing |
| Hypothalamus | Modulates appetite, energy homeostasis | Feeding behavior |
The endocannabinoid system has bidirectional relationship with seizure activity:
CB1 neurons play complex roles in AD pathogenesis:
In PD, CB1 receptors interact with dopaminergic systems:
CB1 neurons contribute to neuroinflammation regulation:
| Drug | Application | Mechanism |
|---|---|---|
| Dronabinol | HIV/AIDS anorexia, chemotherapy nausea | CB1 full agonist |
| Nabilone | Chemotherapy-induced nausea | Synthetic THC analog |
| CBD | Epilepsy (Lennox-Gastaut, Dravet) | FAAH inhibitor, CB1 negative allosteric modulator |
| Drug | Application | Status |
|---|---|---|
| Rimonabant | Obesity (withdrawn) | CB1 inverse agonist |
| TM38837 | Obesity/metabolic disorders | Peripherally-restricted CB1 antagonist |
Peripherally-restricted CB1 antagonists for metabolic diseases
CB1 positive allosteric modulators for neuroprotection
FAAH/MAGL inhibitors to elevate endocannabinoid levels
CB1-CB2 heteromer-selective compounds
Endocannabinoid System
Dopamine D2 Receptor Neurons
Hippocampal CA1 Neurons
CNR1 Gene
CB1 Protein
The study of Cannabinoid Cb1 Receptor Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
CB1 receptor expression follows a characteristic pattern across brain regions:
Highest Expression:
Moderate Expression:
Lower Expression:
CB1 receptor expression develops progressively:
| Method | Information Gained |
|---|---|
| Radioligand binding ([3H]CP55,940) | Receptor density, affinity |
| Immunohistochemistry | Cellular and subcellular localization |
| In situ hybridization | CNR1 mRNA distribution |
| Conditional knockout | Cell-type specific function |
| Cre-lox recombination | Circuit-specific manipulation |
Howlett AC, et al. cannabinoid receptor classification. Pharmacol Rev. 2002 Sep;54(2):161-202. 2002. ↩︎
Kano M, et al. Retrograde signaling at cerebellar synapses. Nat Rev Neurosci. 2009 Mar;10(3):223-33. 2009. ↩︎
Zhornitsky S, et al. Cannabidiol in epilepsy: The efficacy and safety of Epidiolex. Pharmaceuticals. 2019 Sep;12(4):140. 2019. ↩︎
Bedse G, et al. Therapeutic targeting of the endocannabinoid system in Alzheimer's disease. Front Pharmacol. 2019 May;10:507. 2019. ↩︎
Martinez-Marignacci M, et al. Cannabinoid receptors in Parkinson's disease. J Parkinsons Dis. 2015;5(4):909-21. 2015. ↩︎
Hebert-Chatelain E, et al. A cannabinoid link to memory. Nature. 2014 Aug;514(7521):S66-9. Available from:. 2014. ↩︎
Di Marzo V. Targeting the endocannabinoid system: To enhance or reduce? Nat Rev Drug Discov. 2009 Jan;8(1):17-23. 2009. ↩︎